Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
10 hedge funds and large institutions have $25.8M invested in Celyad Oncology SA American Depositary Shares in 2015 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
1% more capital invested
Capital invested by funds: $25.4M → $25.8M (+$344K)
0% more funds holding
Funds holding: 10 → 10 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$669K |
| 2 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$431K |
| 3 |
Morgan Stanley
New York
|
+$60.9K |
| 4 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
+$18.6K |
| 5 |
RIM
RS Investment Management
San Francisco,
California
|
+$16.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$3.65M |
| 2 |
PA
Perceptive Advisors
New York
|
-$3.14M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.51K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RIM
1
RS Investment Management
San Francisco,
California
| $16.6M | +$16.8K | +380 | +0.1% |
|
|
CAM
2
Cormorant Asset Management
Boston,
Massachusetts
| $4.09M | – | – | – |
|
|
DCM
3
DAFNA Capital Management
Los Angeles,
California
| $1.64M | – | – | – |
|
4
Bank of America
Charlotte,
North Carolina
| $1.09M | – | – | – |
|
|
VIA
5
Vident Investment Advisory
Alpharetta,
Georgia
| $829K | +$669K | +15,182 | New |
|
|
6
Zurich Cantonal Bank
Zurich,
Switzerland
| $581K | +$18.6K | +422 | +4% |
|
|
OMC
7
Old Mission Capital
Chicago,
Illinois
| $534K | +$431K | +9,776 | New |
|
|
8
Morgan Stanley
New York
| $258K | +$60.9K | +1,381 | +41% |
|
9
UBS Group
Zurich,
Switzerland
| $165K | +$14.6K | +331 | +12% |
|
|
HM
10
HealthCor Management
New York
| – | -$3.65M | -87,181 | Closed |
|
|
PA
11
Perceptive Advisors
New York
| – | -$3.14M | -75,000 | Closed |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| – | -$2.51K | -57 | -92% |
|
CYAD Hedge Fund Activity: Q4 2015 in Review
10 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q4 2015, worth a combined $25.8M — up 1.4% from $25.4M a quarter earlier.
Fund positioning in CYAD was balanced in Q4 2015: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 1 trimmed.
The largest buyer was Vident Investment Advisory, opening a new position worth an estimated $669K. The largest seller was HealthCor Management, exiting entirely with an estimated $3.65M sold.
- 10 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q4 2015, unchanged from Q3 2015.
- Funds reported $25.8M of Celyad Oncology SA American Depositary Shares stock for Q4 2015, up 1.4% quarter-over-quarter.
- 2 funds opened new Celyad Oncology SA American Depositary Shares positions in Q4 2015 and 2 closed out, a net change of 0 holders.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q4 2015 was Vident Investment Advisory, an estimated $669K added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q4 2015 was HealthCor Management, an estimated $3.65M sold.
Based on aggregated 13F filings for Q4 2015.